Promazine is a phenothiazine used to manage schizophrenia. A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity.
- Mechanism
- Curator reviewed
Promazine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Promazine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT2 receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Promazine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with promazine.
- Primary indication
- Used as an adjunct for short term treatment of moderate and severe psychomotor agitation.Curator reviewed · 4 structured indications
- Formula / weight
- C17H20N2S · 284.419 g/mol (avg)
- First approval
- Canada, 1981
- Code names
- A 145 · RP 3276 · Wy 1094
Resolves to
ZGUGWUXLJSTTMA-UHFFFAOYSA-NSMILESCN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12What you can answer from here — as of September 21, 2026
Which drugs share a target with Promazine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account